Cambridge biotechnology startup LinkGevity is developing a revolutionary drug, LINK-001, to target necrosis—believed to be central to ageing. This holistic treatment aims to slow or reverse the ageing process by preventing destructive cellular processes. Early trials are expected by late 2025, with potential implications for various degenerative diseases. Continue reading Targeting Ageing: Cambridge’s Breakthrough Drug Development